Search

Your search keyword '"Bolla, Michel"' showing total 507 results
Start Over Author "Bolla, Michel"
507 results on '"Bolla, Michel"'

1. Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate.

Author

Roy, Soumyajit, Romero, Tahmineh, Michalski, Jeff, Feng, Felix, Efstathiou, Jason, Lawton, Colleen, Bolla, Michel, Maingon, Philippe, de Reijke, Theo, Joseph, David, Ong, Wee, Sydes, Matthew, Dearnaley, David, Tree, Alison, Carrier, Nathalie, Nabid, Abdenour, Souhami, Luis, Incrocci, Luca, Heemsbergen, Wilma, Pos, Floris, Zapatero, Almudena, Guerrero, Araceli, Alvarez, Ana, San-Segundo, Carmen, Maldonado, Xavier, Reiter, Robert, Nickols, Nicholas, Ma, T, Farrell, Matthew, Neilsen, Beth, Juarez, Jesus, Deng, Jie, Vangala, Sitaram, Avril, Norbert, Jia, Angela, Zaorsky, Nicholas, Sun, Yilun, Spratt, Daniel, Kishan, Amar, Rettig, Matthew, Steinberg, Michael, and Valle, Luca

Subjects
Male, Humans, Prostate, Prostatic Neoplasms, Androgen Antagonists, Prostate-Specific Antigen, Adenocarcinoma
Abstract

PURPOSE: The surrogacy of biochemical recurrence (BCR) for overall survival (OS) in localized prostate cancer remains controversial. Herein, we evaluate the surrogacy of BCR using different surrogacy analytic methods. MATERIALS AND METHODS: Individual patient data from 11 trials evaluating radiotherapy dose escalation, androgen deprivation therapy (ADT) use, and ADT prolongation were obtained. Surrogate candidacy was assessed using the Prentice criteria (including landmark analyses) and the two-stage meta-analytic approach (estimating Kendalls tau and the R2). Biochemical recurrence-free survival (BCRFS, time from random assignment to BCR or any death) and time to BCR (TTBCR, time from random assignment to BCR or cancer-specific deaths censoring for noncancer-related deaths) were assessed. RESULTS: Overall, 10,741 patients were included. Dose escalation, addition of short-term ADT, and prolongation of ADT duration significantly improved BCR (hazard ratio [HR], 0.71 [95% CI, 0.63 to 0.79]; HR, 0.53 [95% CI, 0.48 to 0.59]; and HR, 0.54 [95% CI, 0.48 to 0.61], respectively). Adding short-term ADT (HR, 0.91 [95% CI, 0.84 to 0.99]) and prolonging ADT (HR, 0.86 [95% CI, 0.78 to 0.94]) significantly improved OS, whereas dose escalation did not (HR, 0.98 [95% CI, 0.87 to 1.11]). BCR at 48 months was associated with inferior OS in all three groups (HR, 2.46 [95% CI, 2.08 to 2.92]; HR, 1.51 [95% CI, 1.35 to 1.70]; and HR, 2.31 [95% CI, 2.04 to 2.61], respectively). However, after adjusting for BCR at 48 months, there was no significant treatment effect on OS (HR, 1.10 [95% CI, 0.96 to 1.27]; HR, 0.96 [95% CI, 0.87 to 1.06] and 1.00 [95% CI, 0.90 to 1.12], respectively). The patient-level correlation (Kendalls tau) for BCRFS and OS ranged between 0.59 and 0.69, and that for TTBCR and OS ranged between 0.23 and 0.41. The R2 values for trial-level correlation of the treatment effect on BCRFS and TTBCR with that on OS were 0.563 and 0.160, respectively. CONCLUSION: BCRFS and TTBCR are prognostic but failed to satisfy all surrogacy criteria. Strength of correlation was greater when noncancer-related deaths were considered events.

Published
2023

2. Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials

Author

Martin, Ting, Sun, Yilun, Malone, Shawn, Roach, Mack, Dearnaley, David, Pisansky, Thomas M, Feng, Felix Y, Sandler, Howard M, Efstathiou, Jason A, Syndikus, Isabel, Hall, Emma C, Tree, Alison C, Sydes, Matthew R, Cruickshank, Claire, Roy, Soumyajit, Bolla, Michel, Maingon, Philippe, De Reijke, Theo, Nabid, Abdenour, Carrier, Nathalie, Souhami, Luis, Zapatero, Almudena, Guerrero, Araceli, Alvarez, Ana, San-Segundo, Carmen Gonzalez, Maldonado, Xavier, Romero, Tahmineh, Steinberg, Michael L, Valle, Luca F, Rettig, Matthew B, Nickols, Nicholas G, Shoag, Jonathan E, Reiter, Robert E, Zaorsky, Nicholas G, Jia, Angela Y, Garcia, Jorge A, Spratt, Daniel E, Kishan, Amar U, and Investigators, on behalf of the Meta-Analysis of Randomized Trials in Cancer of the Prostate Consortium

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Aging, Clinical Research, Patient Safety, Urologic Diseases, Cancer, Prostate Cancer, Evaluation of treatments and therapeutic interventions, 6.4 Surgery, Good Health and Well Being, Male, Humans, Prostatic Neoplasms, Androgen Antagonists, Androgens, Randomized Controlled Trials as Topic, Prostate-Specific Antigen, Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeThe sequencing of androgen-deprivation therapy (ADT) with radiotherapy (RT) may affect outcomes for prostate cancer in an RT-field size-dependent manner. Herein, we investigate the impact of ADT sequencing for men receiving ADT with prostate-only RT (PORT) or whole-pelvis RT (WPRT).Materials and methodsIndividual patient data from 12 randomized trials that included patients receiving neoadjuvant/concurrent or concurrent/adjuvant short-term ADT (4-6 months) with RT for localized disease were obtained from the Meta-Analysis of Randomized trials in Cancer of the Prostate consortium. Inverse probability of treatment weighting (IPTW) was performed with propensity scores derived from age, initial prostate-specific antigen, Gleason score, T stage, RT dose, and mid-trial enrollment year. Metastasis-free survival (primary end point) and overall survival (OS) were assessed by IPTW-adjusted Cox regression models, analyzed independently for men receiving PORT versus WPRT. IPTW-adjusted Fine and Gray competing risk models were built to evaluate distant metastasis (DM) and prostate cancer-specific mortality.ResultsOverall, 7,409 patients were included (6,325 neoadjuvant/concurrent and 1,084 concurrent/adjuvant) with a median follow-up of 10.2 years (interquartile range, 7.2-14.9 years). A significant interaction between ADT sequencing and RT field size was observed for all end points (P interaction < .02 for all) except OS. With PORT (n = 4,355), compared with neoadjuvant/concurrent ADT, concurrent/adjuvant ADT was associated with improved metastasis-free survival (10-year benefit 8.0%, hazard ratio [HR], 0.65; 95% CI, 0.54 to 0.79; P < .0001), DM (subdistribution HR, 0.52; 95% CI, 0.33 to 0.82; P = .0046), prostate cancer-specific mortality (subdistribution HR, 0.30; 95% CI, 0.16 to 0.54; P < .0001), and OS (HR, 0.69; 95% CI, 0.57 to 0.83; P = .0001). However, in patients receiving WPRT (n = 3,049), no significant difference in any end point was observed in regard to ADT sequencing except for worse DM (HR, 1.57; 95% CI, 1.20 to 2.05; P = .0009) with concurrent/adjuvant ADT.ConclusionADT sequencing exhibits a significant impact on clinical outcomes with a significant interaction with field size. Concurrent/adjuvant ADT should be the standard of care where short-term ADT is indicated in combination with PORT.

Published
2023

3. Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials

Author

Kishan, Amar U, Chu, Fang-I, King, Christopher R, Seiferheld, Wendy, Spratt, Daniel E, Tran, Phuoc, Wang, Xiaoyan, Pugh, Stephanie E, Sandler, Kiri A, Bolla, Michel, Maingon, Philippe, De Reijke, Theo, Nickols, Nicholas G, Rettig, Matthew, Drakaki, Alexandra, Liu, Sandy T, Reiter, Robert E, Chang, Albert J, Feng, Felix Y, Sajed, Dipti, Nguyen, Paul L, Kupelian, Patrick A, Steinberg, Michael L, Boutros, Paul C, Elashoff, David, Collette, Laurence, and Sandler, Howard M

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Prostate Cancer, Radiation Oncology, Cancer, Aging, Clinical Trials and Supportive Activities, Urologic Diseases, Clinical Research, Humans, Male, Neoplasm Grading, Prostatic Neoplasms, Randomized Controlled Trials as Topic, Treatment Failure, Local failure, Radiotherapy, High grade, Urology & Nephrology, Clinical sciences
Abstract

BackgroundThe importance of local failure (LF) after treatment of high-grade prostate cancer (PCa) with definitive radiotherapy (RT) remains unknown.ObjectiveTo evaluate the clinical implications of LF after definitive RT.Design, setting, and participantsIndividual patient data meta-analysis of 992 patients (593 Gleason grade group [GG] 4 and 399 GG 5) enrolled in six randomized clinical trials.Outcome measurements and statistical analysisMultivariable Cox proportional hazard models were developed to evaluate the relationship between overall survival (OS), PCa-specific survival (PCSS), and distant metastasis (DM)-free survival (DMFS) and LF as a time-dependent covariate. Markov proportional hazard models were developed to evaluate the impact of specific transitions between disease states on these endpoints.Results and limitationsMedian follow-up was 6.4 yr overall and 7.2 yr for surviving patients. LF was significantly associated with OS (hazard ratio [HR] 1.70 [95% confidence interval {CI} 1.37-2.10]), PCSS (3.10 [95% CI 2.33-4.12]), and DMFS (HR 1.92 [95% CI 1.54-2.39]), p

Published
2020

4. Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN)

Author

Ma, Ting Martin, Chu, Fang-I, Sandler, Howard, Feng, Felix Y., Efstathiou, Jason A., Jones, Christopher U., Roach, Mack, 3rd, Rosenthal, Seth A., Pisansky, Thomas, Michalski, Jeff M., Bolla, Michel, de Reijke, Theo M., Maingon, Philippe, Neven, Anouk, Denham, James, Steigler, Allison, Joseph, David, Nabid, Abdenour, Souhami, Luis, Carrier, Nathalie, Incrocci, Luca, Heemsbergen, Wilma, Pos, Floris J., Sydes, Matthew R., Dearnaley, David P., Tree, Alison C., Syndikus, Isabel, Hall, Emma, Cruickshank, Clare, Malone, Shawn, Roy, Soumyajit, Sun, Yilun, Zaorsky, Nicholas G., Nickols, Nicholas G., Reiter, Robert E., Rettig, Matthew B., Steinberg, Michael L., Reddy, Vishruth K., Xiang, Michael, Romero, Tahmineh, Spratt, Daniel E., and Kishan, Amar U.

Published
2022
Full Text
View/download PDF

5. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium

Author

Kishan, Amar U., Wang, Xiaoyan, Sun, Yilun, Romero, Tahmineh, Michalski, Jeff M., Ma, Ting Martin, Feng, Felix Y., Sandler, Howard M., Bolla, Michel, Maingon, Philippe, De Reijke, Theo, Neven, Anouk, Steigler, Allison, Denham, James W., Joseph, David, Nabid, Abdenour, Carrier, Nathalie, Souhami, Luis, Sydes, Matt R., Dearnaley, David P., Syndikus, Isabel, Tree, Alison C., Incrocci, Luca, Heemsbergen, Wilma D., Pos, Floris J., Zapatero, Almudena, Efstathiou, Jason A., Guerrero, Araceli, Alvarez, Ana, San-Segundo, Carmen Gonzalez, Maldonado, Xavier, Xiang, Michael, Rettig, Matthew B., Reiter, Robert E., Zaorsky, Nicholas G., Ong, Wee Loon, Dess, Robert T., Steinberg, Michael L., Nickols, Nicholas G., Roy, Soumyajit, Garcia, Jorge A., and Spratt, Daniel E.

Published
2022
Full Text
View/download PDF

6. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis

Author

Kishan, Amar U, Sun, Yilun, Hartman, Holly, Pisansky, Thomas M, Bolla, Michel, Neven, Anouk, Steigler, Allison, Denham, James W, Feng, Felix Y, Zapatero, Almudena, Armstrong, John G, Nabid, Abdenour, Carrier, Nathalie, Souhami, Luis, Dunne, Mary T, Efstathiou, Jason A, Sandler, Howard M, Guerrero, Araceli, Joseph, David, Maingon, Philippe, de Reijke, Theo M, Maldonado, Xavier, Ma, Ting Martin, Romero, Tahmineh, Wang, Xiaoyan, Rettig, Matthew B, Reiter, Robert E, Zaorsky, Nicholas G, Steinberg, Michael L, Nickols, Nicholas G, Jia, Angela Y, Garcia, Jorge A, and Spratt, Daniel E

Published
2022
Full Text
View/download PDF

10. Development of a Novel Robot for Transperineal Needle Based Interventions: Focal Therapy, Brachytherapy and Prostate Biopsies

Author

Long, Jean-Alexandre, Hungr, Nikolai, Baumann, Michael, Descotes, Jean-Luc, Bolla, Michel, Giraud, Jean-Yves, Rambeaud, Jean-Jacques, and Troccaz, Jocelyne

Subjects
Computer Science - Robotics, Physics - Medical Physics
Abstract

Purpose: We report what is to our knowledge the initial experience with a new 3-dimensional ultrasound robotic system for prostate brachytherapy assistance, focal therapy and prostate biopsies. Its ability to track prostate motion intraoperatively allows it to manage motions and guide needles to predefined targets. Materials and Methods: A robotic system was created for transrectal ultrasound guided needle implantation combined with intraoperative prostate tracking. Experiments were done on 90 targets embedded in a total of 9 mobile, deformable, synthetic prostate phantoms. Experiments involved trying to insert glass beads as close as possible to targets in multimodal anthropomorphic imaging phantoms. Results were measured by segmenting the inserted beads in computerized tomography volumes of the phantoms. Results: The robot reached the chosen targets in phantoms with a median accuracy of 2.73 mm and a median prostate motion of 5.46 mm. Accuracy was better at the apex than at the base (2.28 vs 3.83 mm, p <0.001), and similar for horizontal and angled needle inclinations (2.7 vs 2.82 mm, p = 0.18). Conclusions: To our knowledge this robot for prostate focal therapy, brachytherapy and targeted prostate biopsies is the first system to use intraoperative prostate motion tracking to guide needles into the prostate. Preliminary experiments show its ability to reach targets despite prostate motion.

Published
2012
Full Text
View/download PDF

11. Prosper: image and robot-guided prostate brachytherapy

Author

Baumann, Michael, Bolla, Michel, Daanen, Vincent, Descotes, Jean-Luc, Giraud, Jean-Yves, Hungr, Nikolai, Leroy, Antoine, Long, Jean-Alexandre, Martin, Sébastien, and Troccaz, Jocelyne

Subjects
Computer Science - Robotics, Physics - Medical Physics
Abstract

Brachytherapy for localized prostate cancer consists in destroying cancer by introducing iodine radioactive seeds into the gland through hollow needles. The planning of the position of the seeds and their introduction into the prostate is based on intra-operative ultrasound (US) imaging. We propose to optimize the global quality of the procedure by: i) using 3D US; ii) enhancing US data with MRI registration; iii) using a specially designed needle-insertion robot, connected to the imaging data. The imaging methods have been successfully tested on patient data while the robot accuracy has been evaluated on a realistic deformable phantom.

Published
2011

12. MRI/TRUS data fusion for prostate brachytherapy. Preliminary results

Author

Reynier, Christophe, Troccaz, Jocelyne, Fourneret, Philippe, Dusserre, André, Gay-Jeune, Cécile, Descotes, Jean-Luc, Bolla, Michel, and Giraud, Jean-Yves

Subjects
Computer Science - Other Computer Science
Abstract

Prostate brachytherapy involves implanting radioactive seeds (I125 for instance) permanently in the gland for the treatment of localized prostate cancers, e.g., cT1c-T2a N0 M0 with good prognostic factors. Treatment planning and seed implanting are most often based on the intensive use of transrectal ultrasound (TRUS) imaging. This is not easy because prostate visualization is difficult in this imaging modality particularly as regards the apex of the gland and from an intra- and interobserver variability standpoint. Radioactive seeds are implanted inside open interventional MR machines in some centers. Since MRI was shown to be sensitive and specific for prostate imaging whilst open MR is prohibitive for most centers and makes surgical procedures very complex, this work suggests bringing the MR virtually in the operating room with MRI/TRUS data fusion. This involves providing the physician with bi-modality images (TRUS plus MRI) intended to improve treatment planning from the data registration stage. The paper describes the method developed and implemented in the PROCUR system. Results are reported for a phantom and first series of patients. Phantom experiments helped characterize the accuracy of the process. Patient experiments have shown that using MRI data linked with TRUS data improves TRUS image segmentation especially regarding the apex and base of the prostate. This may significantly modify prostate volume definition and have an impact on treatment planning.

Published
2008

13. Medical image computing and computer-aided medical interventions applied to soft tissues. Work in progress in urology

Author

Troccaz, Jocelyne, Baumann, Michael, Berkelman, Peter, Cinquin, Philippe, Daanen, Vincent, Leroy, Antoine, Marchal, Maud, Payan, Yohan, Promayon, Emmanuel, Voros, Sandrine, Bart, Stéphane, Bolla, Michel, Chartier-Kastler, Emmanuel, Descotes, Jean-Luc, Dusserre, Andrée, Giraud, Jean-Yves, Long, Jean-Alexandre, Moalic, Ronan, and Mozer, Pierre

Subjects
Computer Science - Other Computer Science, Computer Science - Robotics
Abstract

Until recently, Computer-Aided Medical Interventions (CAMI) and Medical Robotics have focused on rigid and non deformable anatomical structures. Nowadays, special attention is paid to soft tissues, raising complex issues due to their mobility and deformation. Mini-invasive digestive surgery was probably one of the first fields where soft tissues were handled through the development of simulators, tracking of anatomical structures and specific assistance robots. However, other clinical domains, for instance urology, are concerned. Indeed, laparoscopic surgery, new tumour destruction techniques (e.g. HIFU, radiofrequency, or cryoablation), increasingly early detection of cancer, and use of interventional and diagnostic imaging modalities, recently opened new challenges to the urologist and scientists involved in CAMI. This resulted in the last five years in a very significant increase of research and developments of computer-aided urology systems. In this paper, we propose a description of the main problems related to computer-aided diagnostic and therapy of soft tissues and give a survey of the different types of assistance offered to the urologist: robotization, image fusion, surgical navigation. Both research projects and operational industrial systems are discussed.

Published
2007

16. Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials.

Author

Ma, Ting Martin, Ma, Ting Martin, Sun, Yilun, Malone, Shawn, Roach, Mack, Dearnaley, David, Pisansky, Thomas M, Feng, Felix Y, Sandler, Howard M, Efstathiou, Jason A, Syndikus, Isabel, Hall, Emma C, Tree, Alison C, Sydes, Matthew R, Cruickshank, Claire, Roy, Soumyajit, Bolla, Michel, Maingon, Philippe, De Reijke, Theo, Nabid, Abdenour, Carrier, Nathalie, Souhami, Luis, Zapatero, Almudena, Guerrero, Araceli, Alvarez, Ana, Gonzalez San-Segundo, Carmen, Maldonado, Xavier, Romero, Tahmineh, Steinberg, Michael L, Valle, Luca F, Rettig, Matthew B, Nickols, Nicholas G, Shoag, Jonathan E, Reiter, Robert E, Zaorsky, Nicholas G, Jia, Angela Y, Garcia, Jorge A, Spratt, Daniel E, Kishan, Amar U, Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators, Ma, Ting Martin, Ma, Ting Martin, Sun, Yilun, Malone, Shawn, Roach, Mack, Dearnaley, David, Pisansky, Thomas M, Feng, Felix Y, Sandler, Howard M, Efstathiou, Jason A, Syndikus, Isabel, Hall, Emma C, Tree, Alison C, Sydes, Matthew R, Cruickshank, Claire, Roy, Soumyajit, Bolla, Michel, Maingon, Philippe, De Reijke, Theo, Nabid, Abdenour, Carrier, Nathalie, Souhami, Luis, Zapatero, Almudena, Guerrero, Araceli, Alvarez, Ana, Gonzalez San-Segundo, Carmen, Maldonado, Xavier, Romero, Tahmineh, Steinberg, Michael L, Valle, Luca F, Rettig, Matthew B, Nickols, Nicholas G, Shoag, Jonathan E, Reiter, Robert E, Zaorsky, Nicholas G, Jia, Angela Y, Garcia, Jorge A, Spratt, Daniel E, Kishan, Amar U, and Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators

Abstract

PurposeThe sequencing of androgen-deprivation therapy (ADT) with radiotherapy (RT) may affect outcomes for prostate cancer in an RT-field size-dependent manner. Herein, we investigate the impact of ADT sequencing for men receiving ADT with prostate-only RT (PORT) or whole-pelvis RT (WPRT).Materials and methodsIndividual patient data from 12 randomized trials that included patients receiving neoadjuvant/concurrent or concurrent/adjuvant short-term ADT (4-6 months) with RT for localized disease were obtained from the Meta-Analysis of Randomized trials in Cancer of the Prostate consortium. Inverse probability of treatment weighting (IPTW) was performed with propensity scores derived from age, initial prostate-specific antigen, Gleason score, T stage, RT dose, and mid-trial enrollment year. Metastasis-free survival (primary end point) and overall survival (OS) were assessed by IPTW-adjusted Cox regression models, analyzed independently for men receiving PORT versus WPRT. IPTW-adjusted Fine and Gray competing risk models were built to evaluate distant metastasis (DM) and prostate cancer-specific mortality.ResultsOverall, 7,409 patients were included (6,325 neoadjuvant/concurrent and 1,084 concurrent/adjuvant) with a median follow-up of 10.2 years (interquartile range, 7.2-14.9 years). A significant interaction between ADT sequencing and RT field size was observed for all end points (P interaction < .02 for all) except OS. With PORT (n = 4,355), compared with neoadjuvant/concurrent ADT, concurrent/adjuvant ADT was associated with improved metastasis-free survival (10-year benefit 8.0%, hazard ratio [HR], 0.65; 95% CI, 0.54 to 0.79; P < .0001), DM (subdistribution HR, 0.52; 95% CI, 0.33 to 0.82; P = .0046), prostate cancer-specific mortality (subdistribution HR, 0.30; 95% CI, 0.16 to 0.54; P < .0001), and OS (HR, 0.69; 95% CI, 0.57 to 0.83; P = .0001). However, in patients receiving WPRT (n = 3,049), no significant difference in any end point was observed in regar

Published
2023

17. Biochemical recurrence (BCR) surrogacy for clinical outcomes after radiotherapy for adenocarcinoma of the prostate (BCRSCRAP): A meta-analysis from MARCAP Consortium.

Author

Roy, Soumyajit, primary, Romero, Tahmineh, additional, Steigler, Allison, additional, Denham, James William, additional, Joseph, David John, additional, Michalski, Jeff M., additional, Feng, Felix Y, additional, Bolla, Michel, additional, de Reijke, Theo M., additional, Maingon, Philippe, additional, Sydes, Matthew R., additional, Dearnaley, David P., additional, Incrocci, Luca, additional, Heemsbergen, Wilma, additional, Nabid, Abdenour, additional, Souhami, Luis, additional, Zapatero, Almudena, additional, Sun, Yilun, additional, Spratt, Daniel Eidelberg, additional, and Kishan, Amar Upadhyaya, additional

Published
2023
Full Text
View/download PDF

18. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study

Author

Bosset, Jean-François, Calais, Gilles, Mineur, Laurent, Maingon, Philippe, Stojanovic-Rundic, Suzana, Bensadoun, René-Jean, Bardet, Etienne, Beny, Alexander, Ollier, Jean-Claude, Bolla, Michel, Marchal, Dominique, Van Laethem, Jean-Luc, Klein, Vincent, Giralt, Jordi, Clavère, Pierre, Glanzmann, Christoph, Cellier, Patrice, and Collette, Laurence

Published
2014
Full Text
View/download PDF

20. Local Failure Events in Prostate Cancer Treated with Radiotherapy:A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN)

Author

Ma, Ting Martin, Chu, Fang I., Sandler, Howard, Feng, Felix Y., Efstathiou, Jason A., Jones, Christopher U., Roach, Mack, Rosenthal, Seth A., Pisansky, Thomas, Michalski, Jeff M., Bolla, Michel, de Reijke, Theo M., Maingon, Philippe, Neven, Anouk, Denham, James, Steigler, Allison, Joseph, David, Nabid, Abdenour, Souhami, Luis, Carrier, Nathalie, Incrocci, Luca, Heemsbergen, Wilma, Pos, Floris J., Sydes, Matthew R., Dearnaley, David P., Tree, Alison C., Syndikus, Isabel, Hall, Emma, Cruickshank, Clare, Malone, Shawn, Roy, Soumyajit, Sun, Yilun, Zaorsky, Nicholas G., Nickols, Nicholas G., Reiter, Robert E., Rettig, Matthew B., Steinberg, Michael L., Reddy, Vishruth K., Xiang, Michael, Romero, Tahmineh, Spratt, Daniel E., Kishan, Amar U., Ma, Ting Martin, Chu, Fang I., Sandler, Howard, Feng, Felix Y., Efstathiou, Jason A., Jones, Christopher U., Roach, Mack, Rosenthal, Seth A., Pisansky, Thomas, Michalski, Jeff M., Bolla, Michel, de Reijke, Theo M., Maingon, Philippe, Neven, Anouk, Denham, James, Steigler, Allison, Joseph, David, Nabid, Abdenour, Souhami, Luis, Carrier, Nathalie, Incrocci, Luca, Heemsbergen, Wilma, Pos, Floris J., Sydes, Matthew R., Dearnaley, David P., Tree, Alison C., Syndikus, Isabel, Hall, Emma, Cruickshank, Clare, Malone, Shawn, Roy, Soumyajit, Sun, Yilun, Zaorsky, Nicholas G., Nickols, Nicholas G., Reiter, Robert E., Rettig, Matthew B., Steinberg, Michael L., Reddy, Vishruth K., Xiang, Michael, Romero, Tahmineh, Spratt, Daniel E., and Kishan, Amar U.

Abstract

Context: The prognostic importance of local failure after definitive radiotherapy (RT) in National Comprehensive Cancer Network intermediate- and high-risk prostate cancer (PCa) patients remains unclear. Objective: To evaluate the prognostic impact of local failure and the kinetics of distant metastasis following RT. Evidence acquisition: A pooled analysis was performed on individual patient data of 12 533 PCa (6288 high-risk and 6245 intermediate-risk) patients enrolled in 18 randomized trials (conducted between 1985 and 2015) within the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium. Multivariable Cox proportional hazard (PH) models were developed to evaluate the relationship between overall survival (OS), PCa-specific survival (PCSS), distant metastasis-free survival (DMFS), and local failure as a time-dependent covariate. Markov PH models were developed to evaluate the impact of specific transition states. Evidence synthesis: The median follow-up was 11 yr. There were 795 (13%) local failure events and 1288 (21%) distant metastases for high-risk patients and 449 (7.2%) and 451 (7.2%) for intermediate-risk patients, respectively. For both groups, 81% of distant metastases developed from a clinically relapse-free state (cRF state). Local failure was significantly associated with OS (hazard ratio [HR] 1.17, 95% confidence interval [CI] 1.06–1.30), PCSS (HR 2.02, 95% CI 1.75–2.33), and DMFS (HR 1.94, 95% CI 1.75–2.15, p < 0.01 for all) in high-risk patients. Local failure was also significantly associated with DMFS (HR 1.57, 95% CI 1.36–1.81) but not with OS in intermediate-risk patients. Patients without local failure had a significantly lower HR of transitioning to a PCa-specific death state than those who had local failure (HR 0.32, 95% CI 0.21–0.50, p < 0.001). At later time points, more distant metastases emerged after a local failure event for both groups. Conclusions: Local failure is an independent prognosticator of OS, PCSS

Published
2022

22. Local failure, distant metastasis, and survival after definitive radiotherapy for intermediate- and high-risk prostate cancer: An individual patient-level meta-analysis of 18 randomized trials.

Author

Ma, Ting Martin, primary, Chu, Fang-I, additional, Romero, Tahmineh, additional, Michalski, Jeff M., additional, Pisansky, Thomas Michael, additional, Roach, Mack, additional, Feng, Felix Y, additional, Sandler, Howard M., additional, Bolla, Michel, additional, Neven, Anouk, additional, Incrocci, Luca, additional, Sydes, Matthew R., additional, Nabid, Abdenour, additional, Denham, James William, additional, Steigler, Allison, additional, Souhami, Luis, additional, Armstrong, John, additional, Malone, Shawn, additional, Spratt, Daniel Eidelberg, additional, and Kishan, Amar Upadhyaya, additional

Published
2022
Full Text
View/download PDF

24. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study

Author

Bolla, Michel, Van Tienhoven, Geertjan, Warde, Padraig, Dubois, Jean Bernard, Mirimanoff, René-Olivier, Storme, Guy, Bernier, Jacques, Kuten, Abraham, Sternberg, Cora, Billiet, Ignace, Torecilla, José Lopez, Pfeffer, Raphael, Cutajar, Carmel Lino, Van der Kwast, Theodore, and Collette, Laurence

Published
2010
Full Text
View/download PDF

27. Association of Increased Prostate-Specific Antigen Levels After Treatment and Mortality in Men With Locally Advanced vs Localized Prostate Cancer

Author

King, Martin T., Chen, Ming-Hui, Collette, Laurence, Neven, Anouk, Bolla, Michel, and D’Amico, Anthony V.

Subjects
Male, Time Factors, Antineoplastic Agents, Hormonal, Research, Prostatic Neoplasms, Androgen Antagonists, Prostate-Specific Antigen, Cohort Studies, Online Only, Oncology, Belgium, Biomarkers, Tumor, Humans, Neoplasm Metastasis, Original Investigation, Aged, Boston, Randomized Controlled Trials as Topic
Abstract

Key Points Question Is the association between increased prostate-specific antigen levels after treatment (PSA failure) and the risk of death different in men with locally advanced compared with localized prostate cancer? Findings In this cohort study of men from 2 randomized clinical trials, PSA failure was associated with a higher risk of death in a trial of locally advanced cancer compared with a trial of localized prostate cancer. Meaning These findings suggest that PSA failure may be associated with a worse outcome in men who have locally advanced rather than localized prostate cancer., Importance Increased prostate-specific antigen (PSA) levels after treatment (PSA failure) may have different associations with outcomes for men with locally advanced vs localized prostate cancer. Objective To evaluate whether the association between PSA failure and death may be different in locally advanced vs localized prostate cancer. Design, Setting, and Participants This multicenter cohort study included patients from 2 randomized clinical trials. The Dana-Farber Cancer Institute (DFCI) 95-096 trial randomized 206 men with localized prostate cancer from December 1, 1995, to April 15, 2001, whereas the European Organisation for Research and Treatment of Cancer (EORTC) 22961 trial randomized 970 men with locally advanced prostate cancer from October 30, 1997, to May 1, 2002. Data were analyzed from January 1, 2020, to October 31, 2020. Interventions The DFCI 95-096 trial randomized men to 0 vs 6 months of androgen deprivation therapy (ADT) with external beam radiotherapy; the EORTC 22961 trial randomized men to 6 vs 36 months of ADT with external beam radiotherapy. Main Outcomes and Measures For each trial, the PSA doubling time (time to doubling of PSA levels) associated with PSA failure was evaluated. The risk of all-cause mortality associated with PSA failure (nadir plus 2 definition) was evaluated after adjustment of baseline covariates and treatment. Results This analysis included a total of 1173 men (206 from DFCI 95-096 and 967 with available tumor stage from EORTC 22961; median age, 70.0 [interquartile range (IQR), 65.0-74.0 years). For DFCI 95-096, 161 men died (30 [18.6%] due to prostate cancer) at a median follow-up of 18.2 (IQR, 17.3-18.8) years. Among the 108 men with PSA failure, the median PSA doubling time was 13.0 (IQR, 7.4-31.1) months. For EORTC 22961, 230 men died (75 [32.6%] due to prostate cancer) at a median follow-up of 6.4 (IQR, 6.3-6.6) years. Among 290 men who experienced PSA failure, the median PSA doubling time was 5.0 (IQR, 2.9-8.9) months. Compared with DFCI 95-096, PSA failure was associated with a higher risk of all-cause mortality in EORTC 22961 (adjusted hazard ratios, 3.98 [95% CI, 2.92-5.44]; P, This cohort study evaluates whether the association between prostate-specific antigen (PSA) failure and death may be different in men with locally advanced vs localized prostate cancer enrolled in 2 randomized clinical trials.

Published
2021

31. Duration of androgen suppression in the treatment of prostrate cancer

Author

Bolla, Michel, de Reijke, Theodorus M., Van Tienhoven, Geertjan, Van den Bergh, Alphonsus, Oddens, Jorg, Poortmans, Philip M.P., Gez, Eliahu, Kil, Paul, Akdas, Atif, Soete, Guy, Kariakine, Oleg, van der Steen-Banasik Elsbietha M., Musat, Elena, Pierart, Marianne, Mauer, Murielle E., and Coliette, Laurence

Subjects
Radiotherapy -- Usage, Radiotherapy -- Health aspects, Prostate cancer -- Care and treatment
Abstract

The study aims to compare the efficacy of radiotherapy along with long-term suppression of androgen against radio therapy with short-term androgen suppression in the treatment of patients with prostrate cancer. The results indicate that long-term therapy of three years or more was far more effective as compared to that of six months or so.

Published
2009

32. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees

Author

Witjes, J. Alfred, Babjuk, Marek, Bellmunt, Joaquim, Bruins, H. Maxim, De Reijke, Theo M., De Santis, Maria, Gillessen, Silke, James, Nicholas, Maclennan, Steven, Palou, Juan, Powles, Tom, Ribal, Maria J., Shariat, Shahrokh F., Van der Kwast, Theo, Xylinas, Evanguelos, Agarwal, Neeraj, Arends, Tom, Bamias, Aristotle, Birtle, Alison, Black, Peter C., Bochner, Bernard H., Bolla, Michel, Boormans, Joost L., Bossi, Alberto, Briganti, Alberto, Brummelhuis, Iris, Burger, Max, Castellano, Daniel, Cathomas, Richard, Chiti, Arturo, Choudhury, Ananya, Comperat, Eva, Crabb, Simon, Culine, Stephane, De Bari, Berardino, De Blok, Willem, De Visschere, Pieter J. L., Decaestecker, Karel, Dimitropoulos, Konstantinos, Dominguez-Escrig, Jose L., Fanti, Stefano, Fonteyne, Valerie, Frydenberg, Mark, Futterer, Jurgen J., Gakis, Georgios, Geavlete, Bogdan, Gontero, Paolo, Grubmueller, Bernhard, Hafeez, Shaista, Jones, Rob, and Leliveld-Kors, A. M.

Subjects
METASTATIC UROTHELIAL CARCINOMA, Consensus, Follow-up, education, Bladder cancer, CISPLATIN-INELIGIBLE PATIENTS, LONG-TERM-SURVIVAL, Delphi, Treatment, PROGNOSTIC-FACTORS, Diagnosis, TUMOR RESPONSE, SINGLE-ARM, RADICAL CYSTECTOMY, LYMPHOCYTE RATIO, TRANSITIONAL-CELL CARCINOMA
Abstract

Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference. Setting: Online Delphi survey and consensus conference. Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1–3 (disagree), 4–6 (equivocal), and 7–9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). Results and limitations: Overall, 116 statements were included in the Delphi survey. Of these statements, 33 (28%) achieved level 1 consensus and 49 (42%) achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease, and the evolving role of checkpoint inhibitor therapy in metastatic disease. Conclusions: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time when further evidence is available to guide our approach. Patient summary: This report summarises findings from an international, multistakeholder project organised by the EAU and ESMO. In this project, a steering committee identified areas of bladder cancer management where there is currently no good-quality evidence to guide treatment decisions. From this, they developed a series of proposed statements, 71 of which achieved consensus by a large group of experts in the field of bladder cancer. It is anticipated that these statements will provide further guidance to health care professionals and could help improve patient outcomes until a time when good-quality evidence is available.

Published
2020

33. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multistakeholder effort† EU*ACME: under the auspices of the EAU-ESMO guidelines committees

Author

Witjes, J Alfred, Babjuk, Marek, Bellmunt, Joaquim, Bruins, H Maxim, De Reijke, Theo M, De Santis, Maria, Gillessen, Silke, James, Nicholas, Maclennan, Steven, Palou, Juan, Powles, Tom, Ribal, Maria J, Shariat, Shahrokh F, Der Kwast, Theo Van, Xylinas, Evanguelos, Agarwal, Neeraj, Arends, Tom, Bamias, Aristotle, Birtle, Alison, Black, Peter C, Bochner, Bernard H, Bolla, Michel, Boormans, Joost L, Bossi, Alberto, Briganti, Alberto, Brummelhuis, Iris, Burger, Max, Castellano, Daniel, Cathomas, Richard, Chiti, Arturo, Choudhury, Ananya, Compérat, Eva, Crabb, Simon, Culine, Stephane, De Bari, Berardino, De Blok, Willem, J L De Visschere, Pieter, Decaestecker, Karel, Dimitropoulos, Konstantinos, Dominguez-Escrig, Jose L, Fanti, Stefano, Fonteyne, Valerie, Frydenberg, Mark, Futterer, Jurgen J, Gakis, Georgios, Geavlete, Bogdan, Gontero, Paolo, Grubmüller, Bernhard, Hafeez, Shaista, Hansel, Donna E, Hartmann, Arndt, Hayne, Dickon, Henry, Ann M, Hernandez, Virginia, Herr, Harry, Herrmann, Ken, Hoskin, Peter, Huguet, Jorge, Jereczek-Fossa, Barbara A, Jones, Rob, Kamat, Ashish M, Khoo, Vincent, Kiltie, Anne E, Krege, Susanne, Ladoire, Sylvain, Lara, Pedro C, Leliveld, Annemarie, Linares-Espinós, Estefania, Løgager, Vibeke, Lorch, Anja, Loriot, Yohann, Meijer, Richard, Mir, M Carmen, Moschini, Marco, Mostafid, Hugh, Müller, Arndt-Christian, Müller, Christoph R, N'Dow, James, Necchi, Andrea, Neuzillet, Yann, Oddens, Jorg R, Oldenburg, Jan, Osanto, Susanne, J G Oyen, Wim, Pacheco-Figueiredo, Luís, Pappot, Helle, Patel, Manish I, Pieters, Bradley R, Plass, Karin, Remzi, Mesut, Retz, Margitta, Richenberg, Jonathan, Rink, Michael, Roghmann, Florian, Rosenberg, Jonathan E, Rouprêt, Morgan, Rouvière, Olivier, Salembier, Carl, Salminen, Antti, Sargos, Paul, Sengupta, Shomik, Sherif, Amir, Smeenk, Robert J, Smits, Anita, Stenzl, Arnulf, Thalmann, George N, Tombal, Bertrand, Turkbey, Baris, Lauridsen, Susanne Vahr, Valdagni, Riccardo, Der Heijden, Antoine G Van, Van Poppel, Hein, Vartolomei, Mihai D, Veskimäe, Erik, Vilaseca, Antoni, Rivera, Franklin A Vives, Wiegel, Thomas, Wiklund, Peter, Williams, Andrew, Zigeuner, Richard, and Horwich, Alan

Subjects
education
Abstract

Background: \ud Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial.\ud \ud Objective: \ud To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management.\ud \ud Design: \ud A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference.\ud \ud Setting: \ud Online Delphi survey and consensus conference.\ud \ud Participants: \ud The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management.\ud \ud Outcome measurements and statistical analysis: \ud Statements were ranked by experts according to their level of agreement: 1–3 (disagree), 4–6 (equivocal), and 7–9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus).\ud \ud Results and limitations: \ud Overall, 116 statements were included in the Delphi survey. Of these statements, 33 (28%) achieved level 1 consensus and 49 (42%) achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease, and the evolving role of checkpoint inhibitor therapy in metastatic disease.\ud \ud Conclusions: \ud These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time when further evidence is available to guide our approach.\ud \ud Patient summary: \ud This report summarises findings from an international, multistakeholder project organised by the EAU and ESMO. In this project, a steering committee identified areas of bladder cancer management where there is currently no good-quality evidence to guide treatment decisions. From this, they developed a series of proposed statements, 71 of which achieved consensus by a large group of experts in the field of bladder cancer. It is anticipated that these statements will provide further guidance to health care professionals and could help improve patient outcomes until a time when good-quality evidence is available.

Published
2020

34. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort †[Formula presented] : Under the Auspices of the EAU-ESMO Guidelines Committees

Author

Witjes, J. Alfred, Babjuk, Marek, Bellmunt, Joaquim, Bruins, H. Maxim, de Reijke, Theo M., de Santis, Maria, Gillessen, Silke, James, Nicholas, Maclennan, Steven, Palou, Juan, Powles, Tom, Ribal, Maria J., Shariat, Shahrokh F., der Kwast, Theo Van, Xylinas, Evanguelos, Agarwal, Neeraj, Arends, Tom, Bamias, Aristotle, Birtle, Alison, Black, Peter C., Bochner, Bernard H., Bolla, Michel, Boormans, Joost L., Bossi, Alberto, Briganti, Alberto, Brummelhuis, Iris, Burger, Max, Castellano, Daniel, Cathomas, Richard, Chiti, Arturo, Choudhury, Ananya, Compérat, Eva, Crabb, Simon, Culine, Stephane, de Bari, Berardino, de Blok, Willem, J.l. de Visschere, Pieter, Decaestecker, Karel, Dimitropoulos, Konstantinos, Dominguez-Escrig, Jose L., Fanti, Stefano, Fonteyne, Valerie, Frydenberg, Mark, Futterer, Jurgen J., Gakis, Georgios, Geavlete, Bogdan, Gontero, Paolo, Grubmüller, Bernhard, Hafeez, Shaista, Hansel, Donna E., Hartmann, Arndt, Hayne, Dickon, Henry, Ann M., Hernandez, Virginia, Herr, Harry, Herrmann, Ken, Hoskin, Peter, Huguet, Jorge, Jereczek-Fossa, Barbara A., Jones, Rob, Kamat, Ashish M., Khoo, Vincent, Kiltie, Anne E., Krege, Susanne, Ladoire, Sylvain, Lara, Pedro C., Leliveld, Annemarie, Linares-Espinós, Estefania, Løgager, Vibeke, Lorch, Anja, Loriot, Yohann, Meijer, Richard, Mir, M. Carmen, Moschini, Marco, Mostafid, Hugh, Müller, Arndt-Christian, Müller, Christoph R., N'Dow, James, Necchi, Andrea, Neuzillet, Yann, Oddens, Jorg R., Oldenburg, Jan, Osanto, Susanne, J.G. Oyen, Wim, Pacheco-Figueiredo, Luís, Pappot, Helle, Patel, Manish I., Pieters, Bradley R., Plass, Karin, Remzi, Mesut, Retz, Margitta, Richenberg, Jonathan, Rink, Michael, Roghmann, Florian, Rosenberg, Jonathan E., Rouprêt, Morgan, Rouvière, Olivier, Salembier, Carl, Salminen, Antti, Sargos, Paul, Sengupta, Shomik, Sherif, Amir, Smeenk, Robert J., Smits, Anita, Stenzl, Arnulf, Thalmann, George N., Tombal, Bertrand, Turkbey, Baris, Lauridsen, Susanne Vahr, Valdagni, Riccardo, der Heijden, Antoine G. Van, van Poppel, Hein, Vartolomei, Mihai D., Veskimäe, Erik, Vilaseca, Antoni, Rivera, Franklin A. Vives, Wiegel, Thomas, Wiklund, Peter, Williams, Andrew, Zigeuner, Richard, Horwich, Alan, Urology, APH - Personalized Medicine, APH - Quality of Care, CCA - Cancer Treatment and Quality of Life, and Radiotherapy

Subjects
Consensus, International Cooperation, Follow-up, Urology, education, Bladder cancer, Delphi, Treatment, Diagnosis, Humans, Neoplasm Staging, Urinary Bladder Neoplasms, Journal Article
Abstract

Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference. Setting: Online Delphi survey and consensus conference. Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1–3 (disagree), 4–6 (equivocal), and 7–9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). Results and limitations: Overall, 116 statements were included in the Delphi survey. Of these statements, 33 (28%) achieved level 1 consensus and 49 (42%) achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease, and the evolving role of checkpoint inhibitor therapy in metastatic disease. Conclusions: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time when further evidence is available to guide our approach. Patient summary: This report summarises findings from an international, multistakeholder project organised by the EAU and ESMO. In this project, a steering committee identified areas of bladder cancer management where there is currently no good-quality evidence to guide treatment decisions. From this, they developed a series of proposed statements, 71 of which achieved consensus by a large group of experts in the field of bladder cancer. It is anticipated that these statements will provide further guidance to health care professionals and could help improve patient outcomes until a time when good-quality evidence is available.

Published
2020

35. AU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort : Under the Auspices of the EAU-ESMO Guidelines Committees

Author

Witjes, J. Alfred, Babjuk, Marek, Bellmunt, Joaquim, Maxim Bruins, H., De Reijke, Theo M., De Santis, Maria, Gillessen, Silke, James, Nicholas, Maclennan, Steven, Palou, Juan, Powles, Tom, Ribal, Maria J., Shariat, Shahrokh F., Van Der Kwast, Theo, Xylinas, Evanguelos, Agarwal, Neeraj, Arends, Tom, Bamias, Aristotle, Birtle, Alison, Black, Peter C., Bochner, Bernard H., Bolla, Michel, Boormans, Joost L., Bossi, Alberto, Briganti, Alberto, Brummelhuis, Iris, Burger, Max, Castellano, Daniel, Cathomas, Richard, Chiti, Arturo, Choudhury, Ananya, Compérat, Eva, Crabb, Simon, Culine, Stephane, De Bari, Berardino, De Blok, Willem, De Visschere, Pieter J.L., Decaestecker, Karel, Dimitropoulos, Konstantinos, Dominguez-Escrig, Jose L., Fanti, Stefano, Fonteyne, Valerie, Frydenberg, Mark, Futterer, Jurgen J., Gakis, Georgios, Geavlete, Bogdan, Gontero, Paolo, Grubmüller, Bernhard, Hafeez, Shaista, Hansel, Donna E., Hartmann, Arndt, Hayne, Dickon, Henry, Ann M., Hernandez, Virginia, Herr, Harry, Herrmann, Ken, Hoskin, Peter, Huguet, Jorge, Jereczek-Fossa, Barbara A., Jones, Rob, Kamat, Ashish M., Khoo, Vincent, Kiltie, Anne E., Krege, Susanne, Ladoire, Sylvain, Lara, Pedro C., Leliveld, Annemarie, Linares-Espinós, Estefania, Løgager, Vibeke, Lorch, Anja, Loriot, Yohann, Meijer, Richard, Carmen Mir, M., Moschini, Marco, Mostafid, Hugh, Müller, Arndt-Christian, Müller, Christoph R., N’dow, James, Necchi, Andrea, Neuzillet, Yann, Oddens, Jorg R., Oldenburg, Jan, Osanto, Susanne, Oyen, Wim J.G., Pacheco-Figueiredo, Luís, Pappot, Helle, Patel, Manish I., Pieters, Bradley R., Plass, Karin, Remzi, Mesut, Retz, Margitta, Richenberg, Jonathan, Rink, Michael, Roghmann, Florian, Rosenberg, Jonathan E., Rouprêt, Morgan, Rouvière, Olivier, Salembier, Carl, Salminen, Antti, Sargos, Paul, Sengupta, Shomik, Sherif, Amir, Smeenk, Robert J., Smits, Anita, Stenzl, Arnulf, Thalmann, George N., Tombal, Bertrand, Turkbey, Baris, Lauridsen, Susanne Vahr, Valdagni, Riccardo, Van Der Heijden, Antoine G., Van Poppel, Hein, Vartolomei, Mihai D., Veskimäe, Erik, Vilaseca, Antoni, Vives Rivera, Franklin A., Wiegel, Thomas, Wiklund, Peter, Williams, Andrew, Zigeuner, Richard, and Horwich, Alan

Subjects
Medizin
Published
2020

36. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees

Author

Witjes, J. Alfred, Babjuk, Marek, Bellmunt, Joaquim, Bruins, H. Maxim, De Reijke, Theo M., De Santis, Maria, Gillessen, Silke, James, Nicholas, Maclennan, Steven, Palou, Juan, Powles, Tom, Ribal, Maria J., Shariat, Shahrokh F., Van Der Kwast, Theo, Xylinas, Evanguelos, Agarwal, Neeraj, Arends, Tom, Bamias, Aristotle, Birtle, Alison, Black, Peter C., Bochner, Bernard H., Bolla, Michel, Boormans, Joost L., Bossi, Alberto, Briganti, Alberto, Brummelhuis, Iris, Burger, Max, Castellano, Daniel, Cathomas, Richard, Chiti, Arturo, Choudhury, Ananya, Compérat, Eva, Crabb, Simon, Culine, Stephane, De Bari, Berardino, De Blok, Willem, De Visschere, Pieter J.L., Decaestecker, Karel, Dimitropoulos, Konstantinos, Dominguez-Escrig, Jose L., Fanti, Stefano, Fonteyne, Valerie, Frydenberg, Mark, Futterer, Jurgen J., Gakis, Georgios, Geavlete, Bogdan, Gontero, Paolo, Grubmüller, Bernhard, Hafeez, Shaista, Hansel, Donna E., Hartmann, Arndt, Hayne, Dickon, Henry, Ann M., Hernandez, Virginia, Herr, Harry, Herrmann, Ken, Hoskin, Peter, Huguet, Jorge, Jereczek-Fossa, Barbara A., Jones, Rob, Kamat, Ashish M., Khoo, Vincent, Kiltie, Anne E., Krege, Susanne, Ladoire, Sylvain, Lara, Pedro C., Leliveld, Annemarie, Linares-Espinós, Estefania, Løgager, Vibeke, Lorch, Anja, Loriot, Yohann, Meijer, Richard, Mir, M. Carmen, Moschini, Marco, Mostafid, Hugh, Müller, Arndt-Christian, Müller, Christoph R., N'Dow, James, Necchi, Andrea, Neuzillet, Yann, Oddens, Jorg R., Oldenburg, Jan, Osanto, Susanne, Oyen, Wim J.G., Pacheco-Figueiredo, Luís, Pappot, Helle, Patel, Manish I., Pieters, Bradley R., Plass, Karin, Remzi, Mesut, Retz, Margitta, Richenberg, Jonathan, Rink, Michael, Roghmann, Florian, Rosenberg, Jonathan E., Rouprêt, Morgan, Rouvière, Olivier, Salembier, Carl, Salminen, Antti, Sargos, Paul, Sengupta, Shomik, Sherif, Amir, Smeenk, Robert J., Smits, Anita, Stenzl, Arnulf, Thalmann, George N., Tombal, Bertrand, Turkbey, Baris, Lauridsen, Susanne Vahr, Valdagni, Riccardo, Van Der Heijden, Antoine G., Van Poppel, Hein, Vartolomei, Mihai D., Veskimäe, Erik, Vilaseca, Antoni, Rivera, Franklin A. Vives, Wiegel, Thomas, Wiklund, Peter, Willemse, Peter-Paul M., Williams, Andrew, Zigeuner, Richard, and Horwich, Alan

Subjects
Medizin
Abstract

Korrektur zu 10.1016/j.eururo.2019.09.035

Published
2020

37. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort:Under the Auspices of the EAU-ESMO Guidelines Committees

Author

Witjes, J. Alfred, Babjuk, Marek, Bellmunt, Joaquim, Maxim Bruins, H., De Reijke, Theo M., De Santis, Maria, Gillessen, Silke, James, Nicholas, Maclennan, Steven, Palou, Juan, Powles, Tom, Ribal, Maria J., Shariat, Shahrokh F., Van Der Kwast, Theo, Xylinas, Evanguelos, Agarwal, Neeraj, Arends, Tom, Bamias, Aristotle, Birtle, Alison, Black, Peter C., Bochner, Bernard H., Bolla, Michel, Boormans, Joost L., Bossi, Alberto, Briganti, Alberto, Brummelhuis, Iris, Burger, Max, Castellano, Daniel, Cathomas, Richard, Chiti, Arturo, Choudhury, Ananya, Compérat, Eva, Crabb, Simon, Culine, Stephane, De Bari, Berardino, De Blok, Willem, De Visschere, Pieter J.L., Decaestecker, Karel, Dimitropoulos, Konstantinos, Dominguez-Escrig, Jose L., Fanti, Stefano, Fonteyne, Valerie, Frydenberg, Mark, Futterer, Jurgen J., Gakis, Georgios, Geavlete, Bogdan, Løgager, Vibeke, Müller, Christoph R., Pappot, Helle, and Williams, Andrew

Subjects
Treatment, Consensus, Follow-up, education, Bladder cancer, Diagnosis, Delphi
Abstract

Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference. Setting: Online Delphi survey and consensus conference. Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1–3 (disagree), 4–6 (equivocal), and 7–9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). Results and limitations: Overall, 116 statements were included in the Delphi survey. Of these statements, 33 (28%) achieved level 1 consensus and 49 (42%) achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease, and the evolving role of checkpoint inhibitor therapy in metastatic disease. Conclusions: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time when further evidence is available to guide our approach. Patient summary: This report summarises findings from an international, multistakeholder project organised by the EAU and ESMO. In this project, a steering committee identified areas of bladder cancer management where there is currently no good-quality evidence to guide treatment decisions. From this, they developed a series of proposed statements, 71 of which achieved consensus by a large group of experts in the field of bladder cancer. It is anticipated that these statements will provide further guidance to health care professionals and could help improve patient outcomes until a time when good-quality evidence is available.

Published
2020

39. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort †[Formula presented] : Under the Auspices of the EAU-ESMO Guidelines Committees

Author

Witjes, J Alfred, Babjuk, Marek, Bellmunt, Joaquim, Bruins, H Maxim, De Reijke, Theo M, De Santis, Maria, Gillessen, Silke, James, Nicholas, Maclennan, Steven, Palou, Juan, Powles, Tom, Ribal, Maria J, Shariat, Shahrokh F, Der Kwast, Theo Van, Xylinas, Evanguelos, Agarwal, Neeraj, Arends, Tom, Bamias, Aristotle, Birtle, Alison, Black, Peter C, Bochner, Bernard H, Bolla, Michel, Boormans, Joost L, Bossi, Alberto, Briganti, Alberto, Brummelhuis, Iris, Burger, Max, Castellano, Daniel, Cathomas, Richard, Chiti, Arturo, Choudhury, Ananya, Compérat, Eva, Crabb, Simon, Culine, Stephane, De Bari, Berardino, De Blok, Willem, J L De Visschere, Pieter, Decaestecker, Karel, Dimitropoulos, Konstantinos, Dominguez-Escrig, Jose L, Fanti, Stefano, Fonteyne, Valerie, Frydenberg, Mark, Futterer, Jurgen J, Gakis, Georgios, Geavlete, Bogdan, Gontero, Paolo, Grubmüller, Bernhard, Hafeez, Shaista, Hansel, Donna E, Hartmann, Arndt, Hayne, Dickon, Henry, Ann M, Hernandez, Virginia, Herr, Harry, Herrmann, Ken, Hoskin, Peter, Huguet, Jorge, Jereczek-Fossa, Barbara A, Jones, Rob, Kamat, Ashish M, Khoo, Vincent, Kiltie, Anne E, Krege, Susanne, Ladoire, Sylvain, Lara, Pedro C, Leliveld, Annemarie, Linares-Espinós, Estefania, Løgager, Vibeke, Lorch, Anja, Loriot, Yohann, Meijer, Richard, Mir, M Carmen, Moschini, Marco, Mostafid, Hugh, Müller, Arndt-Christian, Müller, Christoph R, N'Dow, James, Necchi, Andrea, Neuzillet, Yann, Oddens, Jorg R, Oldenburg, Jan, Osanto, Susanne, J G Oyen, Wim, Pacheco-Figueiredo, Luís, Pappot, Helle, Patel, Manish I, Pieters, Bradley R, Plass, Karin, Remzi, Mesut, Retz, Margitta, Richenberg, Jonathan, Rink, Michael, Roghmann, Florian, Rosenberg, Jonathan E, Rouprêt, Morgan, Rouvière, Olivier, Salembier, Carl, Salminen, Antti, Sargos, Paul, Sengupta, Shomik, Sherif, Amir, Smeenk, Robert J, Smits, Anita, Stenzl, Arnulf, Thalmann, George N, Tombal, Bertrand, Turkbey, Baris, Lauridsen, Susanne Vahr, Valdagni, Riccardo, Der Heijden, Antoine G Van, Van Poppel, Hein, Vartolomei, Mihai D, Veskimäe, Erik, Vilaseca, Antoni, Rivera, Franklin A Vives, Wiegel, Thomas, Wiklund, Peter, Williams, Andrew, Zigeuner, Richard, Horwich, Alan, Witjes, J Alfred, Babjuk, Marek, Bellmunt, Joaquim, Bruins, H Maxim, De Reijke, Theo M, De Santis, Maria, Gillessen, Silke, James, Nicholas, Maclennan, Steven, Palou, Juan, Powles, Tom, Ribal, Maria J, Shariat, Shahrokh F, Der Kwast, Theo Van, Xylinas, Evanguelos, Agarwal, Neeraj, Arends, Tom, Bamias, Aristotle, Birtle, Alison, Black, Peter C, Bochner, Bernard H, Bolla, Michel, Boormans, Joost L, Bossi, Alberto, Briganti, Alberto, Brummelhuis, Iris, Burger, Max, Castellano, Daniel, Cathomas, Richard, Chiti, Arturo, Choudhury, Ananya, Compérat, Eva, Crabb, Simon, Culine, Stephane, De Bari, Berardino, De Blok, Willem, J L De Visschere, Pieter, Decaestecker, Karel, Dimitropoulos, Konstantinos, Dominguez-Escrig, Jose L, Fanti, Stefano, Fonteyne, Valerie, Frydenberg, Mark, Futterer, Jurgen J, Gakis, Georgios, Geavlete, Bogdan, Gontero, Paolo, Grubmüller, Bernhard, Hafeez, Shaista, Hansel, Donna E, Hartmann, Arndt, Hayne, Dickon, Henry, Ann M, Hernandez, Virginia, Herr, Harry, Herrmann, Ken, Hoskin, Peter, Huguet, Jorge, Jereczek-Fossa, Barbara A, Jones, Rob, Kamat, Ashish M, Khoo, Vincent, Kiltie, Anne E, Krege, Susanne, Ladoire, Sylvain, Lara, Pedro C, Leliveld, Annemarie, Linares-Espinós, Estefania, Løgager, Vibeke, Lorch, Anja, Loriot, Yohann, Meijer, Richard, Mir, M Carmen, Moschini, Marco, Mostafid, Hugh, Müller, Arndt-Christian, Müller, Christoph R, N'Dow, James, Necchi, Andrea, Neuzillet, Yann, Oddens, Jorg R, Oldenburg, Jan, Osanto, Susanne, J G Oyen, Wim, Pacheco-Figueiredo, Luís, Pappot, Helle, Patel, Manish I, Pieters, Bradley R, Plass, Karin, Remzi, Mesut, Retz, Margitta, Richenberg, Jonathan, Rink, Michael, Roghmann, Florian, Rosenberg, Jonathan E, Rouprêt, Morgan, Rouvière, Olivier, Salembier, Carl, Salminen, Antti, Sargos, Paul, Sengupta, Shomik, Sherif, Amir, Smeenk, Robert J, Smits, Anita, Stenzl, Arnulf, Thalmann, George N, Tombal, Bertrand, Turkbey, Baris, Lauridsen, Susanne Vahr, Valdagni, Riccardo, Der Heijden, Antoine G Van, Van Poppel, Hein, Vartolomei, Mihai D, Veskimäe, Erik, Vilaseca, Antoni, Rivera, Franklin A Vives, Wiegel, Thomas, Wiklund, Peter, Williams, Andrew, Zigeuner, Richard, and Horwich, Alan

Published
2020

40. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees.

Author

UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie, Witjes, J Alfred, Babjuk, Marek, Bellmunt, Joaquim, Bruins, H Maxim, De Reijke, Theo M, De Santis, Maria, Gillessen, Silke, James, Nicholas, Maclennan, Steven, Palou, Juan, Powles, Tom, Ribal, Maria J, Shariat, Shahrokh F, Der Kwast, Theo Van, Xylinas, Evanguelos, Agarwal, Neeraj, Arends, Tom, Bamias, Aristotle, Birtle, Alison, Black, Peter C, Bochner, Bernard H, Bolla, Michel, Boormans, Joost L, Bossi, Alberto, Briganti, Alberto, Brummelhuis, Iris, Burger, Max, Castellano, Daniel, Cathomas, Richard, Chiti, Arturo, Choudhury, Ananya, Compérat, Eva, Crabb, Simon, Culine, Stephane, De Bari, Berardino, De Blok, Willem, J L De Visschere, Pieter, Decaestecker, Karel, Dimitropoulos, Konstantinos, Dominguez-Escrig, Jose L, Fanti, Stefano, Fonteyne, Valerie, Frydenberg, Mark, Futterer, Jurgen J, Gakis, Georgios, Geavlete, Bogdan, Gontero, Paolo, Grubmüller, Bernhard, Hafeez, Shaista, Hansel, Donna E, Hartmann, Arndt, Hayne, Dickon, Henry, Ann M, Hernandez, Virginia, Herr, Harry, Herrmann, Ken, Hoskin, Peter, Huguet, Jorge, Jereczek-Fossa, Barbara A, Jones, Rob, Kamat, Ashish M, Khoo, Vincent, Kiltie, Anne E, Krege, Susanne, Ladoire, Sylvain, Lara, Pedro C, Leliveld, Annemarie, Linares-Espinós, Estefania, Løgager, Vibeke, Lorch, Anja, Loriot, Yohann, Meijer, Richard, Mir, M Carmen, Moschini, Marco, Mostafid, Hugh, Müller, Arndt-Christian, Müller, Christoph R, N'Dow, James, Necchi, Andrea, Neuzillet, Yann, Oddens, Jorg R, Oldenburg, Jan, Osanto, Susanne, J G Oyen, Wim, Pacheco-Figueiredo, Luís, Pappot, Helle, Patel, Manish I, Pieters, Bradley R, Plass, Karin, Remzi, Mesut, Retz, Margitta, Richenberg, Jonathan, Rink, Michael, Roghmann, Florian, Rosenberg, Jonathan E, Rouprêt, Morgan, Rouvière, Olivier, Salembier, Carl, Salminen, Antti, Sargos, Paul, Sengupta, Shomik, Sherif, Amir, Smeenk, Robert J, Smits, Anita, Stenzl, Arnulf, Thalmann, George N, Tombal, Bertrand, Turkbey, Baris, Lauridsen, Susanne Vahr, Valdagni, Riccardo, Der Heijden, Antoine G Van, Van Poppel, Hein, Vartolomei, Mihai D, Veskimäe, Erik, Vilaseca, Antoni, Rivera, Franklin A Vives, Wiegel, Thomas, Wiklund, Peter, Williams, Andrew, Zigeuner, Richard, Horwich, Alan, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie, Witjes, J Alfred, Babjuk, Marek, Bellmunt, Joaquim, Bruins, H Maxim, De Reijke, Theo M, De Santis, Maria, Gillessen, Silke, James, Nicholas, Maclennan, Steven, Palou, Juan, Powles, Tom, Ribal, Maria J, Shariat, Shahrokh F, Der Kwast, Theo Van, Xylinas, Evanguelos, Agarwal, Neeraj, Arends, Tom, Bamias, Aristotle, Birtle, Alison, Black, Peter C, Bochner, Bernard H, Bolla, Michel, Boormans, Joost L, Bossi, Alberto, Briganti, Alberto, Brummelhuis, Iris, Burger, Max, Castellano, Daniel, Cathomas, Richard, Chiti, Arturo, Choudhury, Ananya, Compérat, Eva, Crabb, Simon, Culine, Stephane, De Bari, Berardino, De Blok, Willem, J L De Visschere, Pieter, Decaestecker, Karel, Dimitropoulos, Konstantinos, Dominguez-Escrig, Jose L, Fanti, Stefano, Fonteyne, Valerie, Frydenberg, Mark, Futterer, Jurgen J, Gakis, Georgios, Geavlete, Bogdan, Gontero, Paolo, Grubmüller, Bernhard, Hafeez, Shaista, Hansel, Donna E, Hartmann, Arndt, Hayne, Dickon, Henry, Ann M, Hernandez, Virginia, Herr, Harry, Herrmann, Ken, Hoskin, Peter, Huguet, Jorge, Jereczek-Fossa, Barbara A, Jones, Rob, Kamat, Ashish M, Khoo, Vincent, Kiltie, Anne E, Krege, Susanne, Ladoire, Sylvain, Lara, Pedro C, Leliveld, Annemarie, Linares-Espinós, Estefania, Løgager, Vibeke, Lorch, Anja, Loriot, Yohann, Meijer, Richard, Mir, M Carmen, Moschini, Marco, Mostafid, Hugh, Müller, Arndt-Christian, Müller, Christoph R, N'Dow, James, Necchi, Andrea, Neuzillet, Yann, Oddens, Jorg R, Oldenburg, Jan, Osanto, Susanne, J G Oyen, Wim, Pacheco-Figueiredo, Luís, Pappot, Helle, Patel, Manish I, Pieters, Bradley R, Plass, Karin, Remzi, Mesut, Retz, Margitta, Richenberg, Jonathan, Rink, Michael, Roghmann, Florian, Rosenberg, Jonathan E, Rouprêt, Morgan, Rouvière, Olivier, Salembier, Carl, Salminen, Antti, Sargos, Paul, Sengupta, Shomik, Sherif, Amir, Smeenk, Robert J, Smits, Anita, Stenzl, Arnulf, Thalmann, George N, Tombal, Bertrand, Turkbey, Baris, Lauridsen, Susanne Vahr, Valdagni, Riccardo, Der Heijden, Antoine G Van, Van Poppel, Hein, Vartolomei, Mihai D, Veskimäe, Erik, Vilaseca, Antoni, Rivera, Franklin A Vives, Wiegel, Thomas, Wiklund, Peter, Williams, Andrew, Zigeuner, Richard, and Horwich, Alan

Abstract

BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. OBJECTIVE: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. DESIGN: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference. SETTING: Online Delphi survey and consensus conference. PARTICIPANTS: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), and 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). RESULTS AND LIMITATIONS: Overall, 116 statements were included in the Delphi survey. Of these statements, 33 (28%) achieved level 1 consensus and 49 (42%) achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease, and the evolving role of checkpoint inhibitor therapy in metastatic disease. CONCLUSIONS: These consensus stateme

Published
2020

41. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort †[Formula presented]: Under the Auspices of the EAU-ESMO Guidelines Committees

Author

MS Urologische Oncologie, Cancer, Urologie Medisch volwassenen, Witjes, J Alfred, Babjuk, Marek, Bellmunt, Joaquim, Bruins, H Maxim, De Reijke, Theo M, De Santis, Maria, Gillessen, Silke, James, Nicholas, Maclennan, Steven, Palou, Juan, Powles, Tom, Ribal, Maria J, Shariat, Shahrokh F, Der Kwast, Theo Van, Xylinas, Evanguelos, Agarwal, Neeraj, Arends, Tom, Bamias, Aristotle, Birtle, Alison, Black, Peter C, Bochner, Bernard H, Bolla, Michel, Boormans, Joost L, Bossi, Alberto, Briganti, Alberto, Brummelhuis, Iris, Burger, Max, Castellano, Daniel, Cathomas, Richard, Chiti, Arturo, Choudhury, Ananya, Compérat, Eva, Crabb, Simon, Culine, Stephane, De Bari, Berardino, De Blok, Willem, J L De Visschere, Pieter, Decaestecker, Karel, Dimitropoulos, Konstantinos, Dominguez-Escrig, Jose L, Fanti, Stefano, Fonteyne, Valerie, Frydenberg, Mark, Futterer, Jurgen J, Gakis, Georgios, Geavlete, Bogdan, Gontero, Paolo, Grubmüller, Bernhard, Hafeez, Shaista, Hansel, Donna E, Hartmann, Arndt, Hayne, Dickon, Henry, Ann M, Hernandez, Virginia, Herr, Harry, Herrmann, Ken, Hoskin, Peter, Huguet, Jorge, Jereczek-Fossa, Barbara A, Jones, Rob, Kamat, Ashish M, Khoo, Vincent, Kiltie, Anne E, Krege, Susanne, Ladoire, Sylvain, Lara, Pedro C, Leliveld, Annemarie, Linares-Espinós, Estefania, Løgager, Vibeke, Lorch, Anja, Loriot, Yohann, Meijer, Richard, Mir, M Carmen, Moschini, Marco, Mostafid, Hugh, Müller, Arndt-Christian, Müller, Christoph R, N'Dow, James, Necchi, Andrea, Neuzillet, Yann, Oddens, Jorg R, Oldenburg, Jan, Osanto, Susanne, J G Oyen, Wim, Pacheco-Figueiredo, Luís, Pappot, Helle, Patel, Manish I, Pieters, Bradley R, Plass, Karin, Remzi, Mesut, Retz, Margitta, Richenberg, Jonathan, Rink, Michael, Roghmann, Florian, Rosenberg, Jonathan E, Rouprêt, Morgan, Rouvière, Olivier, Salembier, Carl, Salminen, Antti, Sargos, Paul, Sengupta, Shomik, Sherif, Amir, Smeenk, Robert J, Smits, Anita, Stenzl, Arnulf, Thalmann, George N, Tombal, Bertrand, Turkbey, Baris, Lauridsen, Susanne Vahr, Valdagni, Riccardo, Der Heijden, Antoine G Van, Van Poppel, Hein, Vartolomei, Mihai D, Veskimäe, Erik, Vilaseca, Antoni, Rivera, Franklin A Vives, Wiegel, Thomas, Wiklund, Peter, Williams, Andrew, Zigeuner, Richard, Horwich, Alan, MS Urologische Oncologie, Cancer, Urologie Medisch volwassenen, Witjes, J Alfred, Babjuk, Marek, Bellmunt, Joaquim, Bruins, H Maxim, De Reijke, Theo M, De Santis, Maria, Gillessen, Silke, James, Nicholas, Maclennan, Steven, Palou, Juan, Powles, Tom, Ribal, Maria J, Shariat, Shahrokh F, Der Kwast, Theo Van, Xylinas, Evanguelos, Agarwal, Neeraj, Arends, Tom, Bamias, Aristotle, Birtle, Alison, Black, Peter C, Bochner, Bernard H, Bolla, Michel, Boormans, Joost L, Bossi, Alberto, Briganti, Alberto, Brummelhuis, Iris, Burger, Max, Castellano, Daniel, Cathomas, Richard, Chiti, Arturo, Choudhury, Ananya, Compérat, Eva, Crabb, Simon, Culine, Stephane, De Bari, Berardino, De Blok, Willem, J L De Visschere, Pieter, Decaestecker, Karel, Dimitropoulos, Konstantinos, Dominguez-Escrig, Jose L, Fanti, Stefano, Fonteyne, Valerie, Frydenberg, Mark, Futterer, Jurgen J, Gakis, Georgios, Geavlete, Bogdan, Gontero, Paolo, Grubmüller, Bernhard, Hafeez, Shaista, Hansel, Donna E, Hartmann, Arndt, Hayne, Dickon, Henry, Ann M, Hernandez, Virginia, Herr, Harry, Herrmann, Ken, Hoskin, Peter, Huguet, Jorge, Jereczek-Fossa, Barbara A, Jones, Rob, Kamat, Ashish M, Khoo, Vincent, Kiltie, Anne E, Krege, Susanne, Ladoire, Sylvain, Lara, Pedro C, Leliveld, Annemarie, Linares-Espinós, Estefania, Løgager, Vibeke, Lorch, Anja, Loriot, Yohann, Meijer, Richard, Mir, M Carmen, Moschini, Marco, Mostafid, Hugh, Müller, Arndt-Christian, Müller, Christoph R, N'Dow, James, Necchi, Andrea, Neuzillet, Yann, Oddens, Jorg R, Oldenburg, Jan, Osanto, Susanne, J G Oyen, Wim, Pacheco-Figueiredo, Luís, Pappot, Helle, Patel, Manish I, Pieters, Bradley R, Plass, Karin, Remzi, Mesut, Retz, Margitta, Richenberg, Jonathan, Rink, Michael, Roghmann, Florian, Rosenberg, Jonathan E, Rouprêt, Morgan, Rouvière, Olivier, Salembier, Carl, Salminen, Antti, Sargos, Paul, Sengupta, Shomik, Sherif, Amir, Smeenk, Robert J, Smits, Anita, Stenzl, Arnulf, Thalmann, George N, Tombal, Bertrand, Turkbey, Baris, Lauridsen, Susanne Vahr, Valdagni, Riccardo, Der Heijden, Antoine G Van, Van Poppel, Hein, Vartolomei, Mihai D, Veskimäe, Erik, Vilaseca, Antoni, Rivera, Franklin A Vives, Wiegel, Thomas, Wiklund, Peter, Williams, Andrew, Zigeuner, Richard, and Horwich, Alan

Published
2020

44. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)

Author

Bolla, Michel, van Poppel, Hein, Collette, Laurence, van Cangh, Paul, Vekemans, Kris, Da Pozzo, Luigi, de Reijke, Theo M., Verbaeys, Antony, Bossett, Jean-Francois, van Velthoven, Roland, Marechal, Jean-Marie, Scalliet, Pierre, Haustermans, Karin, and Pierart, Marianne

Subjects
Radiotherapy -- Health aspects, Prostate cancer -- Diagnosis, Prostate cancer -- Care and treatment, Postoperative care
Published
2005

48. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250]

Author

Witjes, J. Alfred, primary, Babjuk, Marek, additional, Bellmunt, Joaquim, additional, Bruins, H. Maxim, additional, De Reijke, Theo M., additional, De Santis, Maria, additional, Gillessen, Silke, additional, James, Nicholas, additional, Maclennan, Steven, additional, Palou, Juan, additional, Powles, Tom, additional, Ribal, Maria J., additional, Shariat, Shahrokh F., additional, Van Der Kwast, Theo, additional, Xylinas, Evanguelos, additional, Agarwal, Neeraj, additional, Arends, Tom, additional, Bamias, Aristotle, additional, Birtle, Alison, additional, Black, Peter C., additional, Bochner, Bernard H., additional, Bolla, Michel, additional, Boormans, Joost L., additional, Bossi, Alberto, additional, Briganti, Alberto, additional, Brummelhuis, Iris, additional, Burger, Max, additional, Castellano, Daniel, additional, Cathomas, Richard, additional, Chiti, Arturo, additional, Choudhury, Ananya, additional, Compérat, Eva, additional, Crabb, Simon, additional, Culine, Stephane, additional, De Bari, Berardino, additional, De Blok, Willem, additional, De Visschere, Pieter J.L., additional, Decaestecker, Karel, additional, Dimitropoulos, Konstantinos, additional, Dominguez-Escrig, Jose L., additional, Fanti, Stefano, additional, Fonteyne, Valerie, additional, Frydenberg, Mark, additional, Futterer, Jurgen J., additional, Gakis, Georgios, additional, Geavlete, Bogdan, additional, Gontero, Paolo, additional, Grubmüller, Bernhard, additional, Hafeez, Shaista, additional, Hansel, Donna E., additional, Hartmann, Arndt, additional, Hayne, Dickon, additional, Henry, Ann M., additional, Hernandez, Virginia, additional, Herr, Harry, additional, Herrmann, Ken, additional, Hoskin, Peter, additional, Huguet, Jorge, additional, Jereczek-Fossa, Barbara A., additional, Jones, Rob, additional, Kamat, Ashish M., additional, Khoo, Vincent, additional, Kiltie, Anne E., additional, Krege, Susanne, additional, Ladoire, Sylvain, additional, Lara, Pedro C., additional, Leliveld, Annemarie, additional, Linares-Espinós, Estefania, additional, Løgager, Vibeke, additional, Lorch, Anja, additional, Loriot, Yohann, additional, Meijer, Richard, additional, Mir, M. Carmen, additional, Moschini, Marco, additional, Mostafid, Hugh, additional, Müller, Arndt-Christian, additional, Müller, Christoph R., additional, N’Dow, James, additional, Necchi, Andrea, additional, Neuzillet, Yann, additional, Oddens, Jorg R., additional, Oldenburg, Jan, additional, Osanto, Susanne, additional, Oyen, Wim J.G., additional, Pacheco-Figueiredo, Luís, additional, Pappot, Helle, additional, Patel, Manish I., additional, Pieters, Bradley R., additional, Plass, Karin, additional, Remzi, Mesut, additional, Retz, Margitta, additional, Richenberg, Jonathan, additional, Rink, Michael, additional, Roghmann, Florian, additional, Rosenberg, Jonathan E., additional, Rouprêt, Morgan, additional, Rouvière, Olivier, additional, Salembier, Carl, additional, Salminen, Antti, additional, Sargos, Paul, additional, Sengupta, Shomik, additional, Sherif, Amir, additional, Smeenk, Robert J., additional, Smits, Anita, additional, Stenzl, Arnulf, additional, Thalmann, George N., additional, Tombal, Bertrand, additional, Turkbey, Baris, additional, Lauridsen, Susanne Vahr, additional, Valdagni, Riccardo, additional, Van Der Heijden, Antoine G., additional, Van Poppel, Hein, additional, Vartolomei, Mihai D., additional, Veskimäe, Erik, additional, Vilaseca, Antoni, additional, Rivera, Franklin A. Vives, additional, Wiegel, Thomas, additional, Wiklund, Peter, additional, Willemse, Peter-Paul M., additional, Williams, Andrew, additional, Zigeuner, Richard, additional, and Horwich, Alan, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results